Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric iptacopan study in paroxysmal nocturnal hemoglobinuria
NL-OMON58853Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Primary endpoints: Safety and tolerability during 26-week treatment period and Pharmacokinetics of iptacopan. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON58853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58853.